Y06036 (50 mg/kg, i.p. injection, 5 times per week, 25 days) demonstrates therapeutic effects in a C4-2B CRPC xenograft tumor model in mice. Y06036 is well tolerated in the treated mice, based on the weight of the animal body and their general behavior[1].
| Animal Model: | Four-week-old male mice (strain: C.B-17/IcrHsd-Prkdcscid for C4-2B) with C4-2B mouse xenograft model[1] |
| Dosage: | 50 mg/kg, 100 μL |
| Administration: | Intraperitoneal (i.p.) injection, 5 times per week, 25 days |
| Result: | Exhibited strong antitumor activities during the 25-day treatment period, with a tumor growth inhibition (TGI) of 70%. |
